FDA 483 - Bioreliance Ltd. - September 27, 2019

An FDA inspection of Bioreliance Ltd. in Glasgow, United Kingdom, a manufacturer of API starting material and control testing laboratory, revealed three significant observations. These included failures to follow written sanitation procedures for equipment cleaning, deficiencies in aseptic simulations for operator qualification, and a lack of quality unit review for equipment changes or repairs during on-demand maintenance.